Imaging Technology

JULY 25, 2023

By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This further strengthens our commitment to production and development of novel radiopharmaceuticals to advance cancer treatments and quality of life for cancer patients."

Radiopharmaceuticals 98

Radiopharmaceuticals Imaging Pharmaceutical Disease 98

Imaging Technology

JULY 11, 2023

By leveraging our expertise in radiopharmaceuticals, we aim to contribute to the early detection and accurate monitoring of epithelial-derived cancers. This partnership exemplifies our commitment to Find, Fight and Follow disease by delivering innovative solutions to improve cancer care, ultimately leading to better patient outcomes."

Radiopharmaceuticals 75

Radiopharmaceuticals Imaging Pharmaceutical Disease 75

Imaging Technology

JULY 20, 2023

milla1cf Thu, 07/20/2023 - 20:11 July 20, 2023 — The members of the American Society for Radiation Oncology ( ASTRO ) recently elected three new officers to ASTRO’s Board of Directors, including Sameer Keole , MD, FASTRO , as President-elect; Wendy Woodward , MD, PhD, FASTRO, as Science Council Vice Chair; and Vivek S.

Radiation Oncology 98

Radiation Oncology Radiation Government Community Practice 98

AuntMinnie

APRIL 4, 2024

A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging.

Nuclear Medicine 222

Nuclear Medicine Radiation Oncology Nursing Radiation 222

Imaging Technology

NOVEMBER 1, 2024

Radiation dosimetry performed for up to three cycles showed delivery of high tumor absorbed radiation doses relative to the dose delivered to the key normal organs, such as kidney and salivary glands. In combination with the positive radiation dosimetry results seen in Phase 1 for Lutetium ( 177 Lu) rhPSMA-10.1

Nuclear Medicine 52

Nuclear Medicine Radiation Radiopharmaceuticals Clinic 52

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 130

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 130

Imaging Technology

APRIL 5, 2024

milla1cf Fri, 04/05/2024 - 11:31 April 5, 2024 — RLS Radiopharmacies , America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler.

Radiopharmaceuticals 52

Radiopharmaceuticals Radiation Oncology Radiation Quality and Compliance 52

Imaging Technology

MAY 14, 2024

Siemens Healthineers and UH will look to also advance the treatment of patients with Alzheimer’s disease and use theranostics—combining the approaches of diagnostics and therapeutics—to treat patients with advanced forms of certain cancers, as well as develop new magnetic resonance ( MR ) technologies. tesla and 3T scanners.

Hospital 116

Hospital Magnetic Resonance Imaging Radiopharmaceuticals Disease 116

Imaging Technology

APRIL 3, 2023

Mr. Merrick continued, “Demand for therapeutic radiopharmaceuticals is increasing rapidly. NorthStar has further deepened and broadened our business platform with the recent establishment of a full-scale radiopharmaceutical CDMO/CMO services unit. Ac-225 using advanced, environmentally preferable electron accelerator technology.

Medical 98

Medical Radiopharmaceuticals Pharmaceutical Radiation 98

Imaging Technology

AUGUST 29, 2023

Once securely attached to a targeting molecule, the chelated Cu-67 delivers therapeutic doses of radiation to destroy cancer cells with limited damage to healthy tissue. It supports a sustainable future for radiopharmaceuticals unencumbered by manufacturing, logistical and environmental issues inherent to many radiopharmaceuticals.

Pharmaceutical 97

Pharmaceutical Radiopharmaceuticals Clinic Medical 97

Imaging Technology

JANUARY 12, 2024

Other technologies use anatomical images to guide radiotherapy delivery; however, SCINTIX therapy is the only radiotherapy to use emissions from cancer cells, created by injecting the patient with a radiopharmaceutical, to deliver a radiation dose that continuously and autonomously targets the cancer itself.

Radiopharmaceuticals 105

Radiopharmaceuticals Radiation Medicare Clinic 105

Imaging Technology

JUNE 29, 2023

milla1cf Thu, 06/29/2023 - 21:10 June 29, 2023 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, today announced highlights from early clinical and preclinical studies of 177Lu-rhPSMA-10.1 higher tumor absorbed radiation dose.

Clinic 98

Clinic Nuclear Medicine Radiopharmaceuticals Radiation 98

Imaging Technology

AUGUST 23, 2023

SCINTIX therapy is a cutting-edge radiopharmaceutical-directed treatment applicable for early and late-stage cancers that uses the individual biology of each tumor to drive its own treatment. “We founder and CTO of RefleXion.

Radiopharmaceuticals 98

Radiopharmaceuticals Disease Radiation Clinic 98

Imaging Technology

APRIL 2, 2024

The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states. "We

Healthcare 105

Healthcare Healthcare Radiation Oncology Magnetic Resonance Imaging 105

Imaging Technology

MAY 2, 2023

milla1cf Tue, 05/02/2023 - 23:50 May 2, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced additional results from its completed Phase 3 SPOTLIGHT trial of 18F-rhPSMA-7.3 18F-rhPSMA-7.3 on behalf of the SPOTLIGHT Study Group.

Diagnostic 98

Diagnostic Radiopharmaceuticals Imaging Radiation 98

Imaging Technology

SEPTEMBER 27, 2023

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Jani, MD, FASTRO, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Ga.,

Diagnostic 105

Diagnostic Radiation Oncology Radiation Clinic 105

Imaging Technology

MAY 30, 2023

milla1cf Tue, 05/30/2023 - 19:49 May 30, 2023 — Blue Earth Diagnostics , a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals , today announced U.S. POSLUMA was developed to assist physicians in the detection and localization of prostate cancer.

Diagnostic 97

Diagnostic Imaging Radiopharmaceuticals Diagnostic Imaging 97

Future Teleradiology

NOVEMBER 27, 2023

Discuss how this approach delivers radiation with exceptional precision to cancer cells. Advances in Cardiac Imaging: Precision in Heart Disease Diagnosis: Highlight recent breakthroughs in cardiac imaging within nuclear medicine. Discuss how these compounds are expanding therapeutic options for various diseases, including cancer.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Imaging Modalities Radiation 52

Imaging Technology

OCTOBER 4, 2024

Specifically, the purpose of dosimetry in radiotherapy is to estimate the amount of dose that will be absorbed by normal tissues and tumors to anticipate the biologic effects of radiation. Dosimetry in Radiopharmaceutical Therapy. Review of fast monte carlo codes for dose calculation in radiation therapy treatment planning.

Radiopharmaceuticals 52

Radiopharmaceuticals Nuclear Medicine Radiation Healthcare 52

Imaging Technology

JULY 28, 2023

POSLUMA represents a new class of high-affinity PSMA-targeted PET radiopharmaceuticals based on novel radiohybrid technology and is labeled with the radioisotope 18F to provide readily available patient access and leverage the high image quality of 18F-labeled PSMA PET imaging to facilitate effective detection of disease.

Diagnostic 98

Diagnostic Clinic Radiopharmaceuticals Radiation 98

Future Teleradiology

NOVEMBER 21, 2023

Advancements in Radiopharmaceuticals: Precision Imaging Agents: Discuss the latest developments in radiopharmaceuticals. Personalized Dosimetry: Optimizing Therapeutic Radiation Doses: Discuss the importance of personalized dosimetry.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Teleradiology 52

Imaging Technology

OCTOBER 5, 2023

Effective initial staging of prostate cancer, particularly with regards to the detection of metastatic disease, is critical to optimal clinical management of patients,” said Phillip H. Such information can help guide treatment selection and potentially avoid futile surgery for patients with high-risk disease.” “We

Diagnose 52

Diagnose Diagnostic Disease Radiation 52

AuntMinnie

SEPTEMBER 30, 2024

A radiopharmaceutical therapy that lengthens progression-free survival for patients with neuroendocrine cancer could help treat meningioma sufferers, according to research presented at the American Society for Radiation Oncology (ASTRO) meeting. Nearly 80% of patients in our study were progression-free after six months," he said.

Radiation Oncology 299

Radiation Oncology Radiopharmaceuticals Radiation Clinic 299

AuntMinnie

OCTOBER 2, 2024

Ultrasound model predicts liver disease progression. Commercially Available Chest Radiograph AI Tools for Detecting Airspace Disease, Pneumothorax, and Pleural Effusion. Effects of low-dose ionizing radiation on genomic instability in interventional radiology workers. SPECT/CT reveals heart’s response to tafamidis.

Digital Imaging and Communications in Medicine 360

Digital Imaging and Communications in Medicine X-ray MRI Hospital 360

AuntMinnie

MARCH 25, 2024

Coronary artery disease (CAD) is the leading cause of mortality in the U.S. In a cohort of 1,282 patients who underwent invasive coronary angiography for suspected disease, noninvasive PET MPI performed within six months identified large perfusion defects (>10% of the left ventricular myocardium) in 82% of the patients.

Nuclear Medicine 321

Nuclear Medicine Radiopharmaceuticals Disease Radiation 321

Imaging Technology

MAY 23, 2023

milla1cf Tue, 05/23/2023 - 11:36 May 23, 2023 — More than 9 in 10 radiation oncologists report that their practices face clinical staff shortages , according to a new national survey from the American Society for Radiation Oncology ( ASTRO ). Radiation oncologists from across the country are in Washington, D.C.

Radiation Oncology 96

Radiation Oncology Radiation Clinic Medicare 96

Imaging Technology

AUGUST 31, 2023

milla1cf Thu, 08/31/2023 - 15:50 August 31, 2023 — NorthStar Medical Radioisotopes , LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals, and Curadh MTR Inc. Ac-225 to Curadh for use in its pioneering molecularly targeted radiation (MTR) programs for the treatment of common lethal tumors. “We

Medical 98

Medical Radiopharmaceuticals Pharmaceutical Radiation 98

Imaging Technology

JULY 5, 2023

Ac-225 is a high energy alpha-emitting radioisotope of increasing interest for clinical studies investigating the use of targeted radiopharmaceutical therapy, which combines select molecules with therapeutic radioisotopes to directly target and deliver therapeutic doses of radiation to destroy cancer cells in patients with serious disease.

Medical 92

Medical Radiopharmaceuticals Pharmaceutical Radiation 92

Global Radiology CME

DECEMBER 21, 2024

The patient is pregnant (orange arrows), therefore ionizing radiation with CT scan or fluoroscopy can not be used for imaging guidance. A nuclear medicine hepatobiliary scan was also performed (not shown) and demonstrated no radiopharmaceutical present in the gallbladder due to cystic duct obstruction. Case Rep Gastroenterol.

Education 52

Education Global Radiology Nuclear Medicine Ultrasound 52